Fore Biotherapeutics
A precision oncology company rooted in science and innovation, developing cancer therapies guided by functional genomics
A precision oncology company rooted in science and innovation, developing cancer therapies guided by functional genomics
Fore Biotherapeutics is a biotechnology startup based in the United States, founded in 2011. The company's slogan, "A precision oncology company rooted in science and innovation, developing cancer therapies guided by functional genomics," reflects its dedication to developing cancer therapies guided by proprietary functional genomics. Fore Biotherapeutics received a significant boost with a $75.00M Series D investment from a consortium of prominent investors including Novartis Venture Fund, OrbiMed, Wellington Management, 3B Future Health Fund, Cormorant Asset Management, HBM Partners, Medicxi Ventures, Samsung Securities, and SR One on 23 August 2023. The company's deep commitment to innovation and compassionate contribution to solving cancer positions it as a promising player in the precision oncology space.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series D | $75.00M | 9 |
|
23 Aug 2023 |
| Convertible Note | Unknown | 2 |
|
17 Oct 2022 |
| Series C | Unknown | 2 |
|
15 Sep 2021 |
| Series C | $57.00M | 7 |
|
21 Sep 2020 |
| Venture Round | $6.00M | 4 |
|
30 Apr 2018 |
No recent news or press coverage available for Fore Biotherapeutics.
We care about your data, and we'd love to use cookies make your experience better.
